In 2023, the actual import value of Erythromycin to Germany stood unobtainable from the provided data. For the forecasted period starting in 2024, there is a consistent decline in import values, with the figures dropping from 7.5087 million USD in 2024 to 7.2249 million USD in 2028. Year-on-year percentage variations indicate a downward trend, suggesting reduced demand or improved domestic production efficiencies. The five-year CAGR indicates average annual declines.

Future trends to watch include:

Shifts in global supply chain dynamics potentially impacting import volumes.
Technological advancements in pharmaceutical production within Germany possibly reducing import reliance.
Policy changes impacting trade relationships and pharmaceutical regulations.